1. Home
  2. RWT vs PHVS Comparison

RWT vs PHVS Comparison

Compare RWT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redwood Trust Inc.

RWT

Redwood Trust Inc.

HOLD

Current Price

$5.53

Market Cap

715.8M

Sector

Real Estate

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.14

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWT
PHVS
Founded
1994
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
715.8M
1.7B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
RWT
PHVS
Price
$5.53
$24.14
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$7.00
$39.44
AVG Volume (30 Days)
1.7M
287.2K
Earning Date
02-12-2026
11-12-2025
Dividend Yield
12.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$120,897,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$46.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.68
$11.51
52 Week High
$6.73
$29.80

Technical Indicators

Market Signals
Indicator
RWT
PHVS
Relative Strength Index (RSI) 48.58 44.99
Support Level $5.49 $23.62
Resistance Level $5.69 $28.43
Average True Range (ATR) 0.13 1.49
MACD -0.02 -0.13
Stochastic Oscillator 25.71 10.81

Price Performance

Historical Comparison
RWT
PHVS

About RWT Redwood Trust Inc.

Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: